PRESS RELEASES

---

Rhythm Names Lex Van der Ploeg Chief Scientific Officer
11/30/11

Rhythm Names Keith M. Gottesdiener Chief Executive Officer
11/09/11

Rhythm Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases
07/26/11

Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
05/09/11

Rhythm Closes $40 Million Series A Financing
09/08/10

Rhythm's RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
06/21/10

Rhythm Announces $21 Million Series A
03/15/10

Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders
03/12/10